Tammie L.S. Benzinger, MD, Ph.D


Neurosciences Program
Biomedical Informatics and Data Science Program

Research Abstract:

Dr. Benzinger`s research focuses on translating advanced neuromagnetic resonance imaging techniques from small animal research in the Department of Radiology, to translational research in the Center for Clinical Imaging Research (CCIR), and into clinical practice. In particular, her current research focuses on using directional diffusivity measurements derived from diffusion tensor imaging (DTI) to measure axonal and myelin damage in pediatric and adult demyelination, dysmyelinating diseases, in traumatic brain injury (TBI), and as a function of aging. Diseases under study in Dr. Benzinger`s laboratory include multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), adrenoleukodystrophy, Krabbe`s disease, Pelizaeus-Merzbacher`s disease, and head trauma. In addition, Dr. Benzinger combines advanced neuromagnetic resonance techniques, such as DTI and spectroscopy, and positron emission tomography (PET) to study interactions between normal aging, Alzherimer`s disease, depression, and delirium in older adults.

Selected Publications:

Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, Benzinger TL. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. JAMA Neurol. 2016 Oct 1;73(10):1192-1200. PubMed Central PMCID: PMC5237381.

Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, Aldea P, McConathy J, Holtzman DM, Cairns NJ, Morris JC, Fagan AM, Ances BM, Benzinger TL. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain. 2016 Aug;139(Pt 8):2249-60. PubMed Central PMCID: PMC4958902.

Vos SJ, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC, Fagan AM, Benzinger TL. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging. 2016 Aug;44:1-8. PubMed Central PMCID: PMC4913039.

Mishra S, Gordon BA, Su Y, Christensen J, Friedrichsen K, Jackson K, Hornbeck R, Balota DA, Cairns, NJ, Morris JC, Ances BM, Benzinger TLS. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. Neuroimage 2017;161:171-8. PubMed Central PMCID: PMC5696044.

Dominantly inherited Alzheimer disease: Since 2010, I have been involved in autosomal dominant Alzheimer`s disease as part of the Dominantly Inherited Alzheimer Network (DIAN, UF1AG032438) and its associated Trials Unit (DIAN-TU, U01 AG042791). As Imaging Core Leader for DIAN and DIAN-TU, I am responsible for MRI and PET protocols, site setup, imaging QC, processing, and primary imaging analyses. Through the work of DIAN, we established the first proof of a 20-year phase of amyloid positivity, prior to symptom onset, in our 2012 New England Journal of Medicine publication. We further elaborated this in 2013 with a detailed regional analysis of MRI and PET findings in the DIAN cohort. Through this work, we have also made significant contributions to image processing, including the problem of partial volume correction in PET and use of image-derived arterial input functions.

Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC. Clinical and biomarker changes in dominantly inherited Alzheimer`s disease. N Engl J Med. 2012 Aug 30;367(9):795-804. PubMed Central PMCID: PMC3474597.

Benzinger TL*, Blazey T*, Jack CR Jr, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, Christensen JJ, Ercole L, Hornbeck RC, Farrar AM, Aldea P, Jasielec MS, Owen CJ, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis CA, Ringman J, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Salloway S, Correia S, Schofield PR, Masters CL, Rowe C, Villemagne VL, Martins R, Ourselin S, Rossor MN, Fox NC, Cash DM, Weiner MW, Holtzman DM, Buckles VD, Moulder K, Morris JC. Regional variability of imaging biomarkers in autosomal dominant Alzheimer`s disease. Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):E4502-9. PubMed Central PMCID: PMC3839740.

Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer`s Disease: Results from the DIAN Study Group. PLoS One. 2016 Sep 20;11(9):e0163669. PubMed Central PMCID:PMC4807073.

Gordon B, Blazey T, Su Y, Hari-Raj A, Dincer A, Ances B, Flores S, Christensen J, McDade E, Wang G, iong C, Cairns NJ, Hassenstab J, Marcus DS, Fangan AM, Jack Jr C, Hornbeck R, Paumier K, Berman BM, Brickman A, Cash D, Chhatwal J, Correia S, Forster S, Fox NC, Graff-Radford NR, Fougere C, Levin J, Masters CL, Rosser M, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner M, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS, Dominantly Inherited Alzheimer N. Spatial patterns of longitudinal neuroimaging biomarker change in autosomal dominant Alzheimer disease. Lancet neurology. 2018 Mar;17(3):241-250. PubMed PMID: 29397305; PMCID: PMC5816717

Complete List of Published Work in My Bibliography: https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/40199677

Last Updated: 10/5/2018 9:30:56 AM

Beta-amyloid deposition in pre-symptomatic and symptomatic carriers of Alzheimer`s disease-causing gene mutations.
Back To Top

Follow us: